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Abstract 
Background: There is a lack of guidance on how population estimates should be obtained for expected 
value of information (EVI) analysis. We argue that disregarding uptake may lead to over-estimation 
of the population EVI (PEVI).   
Aims: To investigate how population estimates for PEVI analyses were obtained, whether they were 
adjusted by uptake and what methods were employed to obtain the uptake estimates. 
Methods: A literature search and review was conducted using the NHS Economic Evaluation 
Database (EED) and prior knowledge of relevant publications. Publications were excluded when they 
did not report PEVI estimates or were duplicates.  
Results: Out of 43 records resulting from the CRD search and 3 relevant publications that were known 
to us prior to this study, 29 studies were included. Out of these, 27 had not adjusted their population 
estimate by uptake levels. The remaining 2 studies had obtained their uptake estimates from uptake 
levels reported in trials and based on assumption. Only 5 studies acknowledged uncertainty associated 
with the population estimate used.  
Conclusion: Based on the result that very few PEVI studies had adjusted their population estimate by 
uptake and taking into account the large downward effect that uptake adjustments could have on the 
value of PEVI estimates, there is a need for discussion and further research around uptake adjustments 
in PEVI analyses. 
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Background 
There is a lack of guidance on how population estimates should be obtained for expected value of 
information (EVI) analysis. The EVI is used in economic evaluations to assess the value of reducing 
decision uncertainty through further research. To obtain the overall value that can be derived from 
research in a health system or society, the EVI is then often aggregated over the population that may 
potentially benefit and the time horizon that research may be relevant to, resulting in the population 
EVI (PEVI). While there has been some discussion on what time horizon to apply in EVI analyses 
(Philips, Claxton et al. 2008), methods of obtaining population estimates are less clear.  
We argue here that disregarding uptake may lead to over-estimation of PEVIs. Not all patients will 
benefit from research on a new intervention as technology uptake may be low. This has previously 
been acknowledged by Fenwick, Claxton et al. (2008). Furthermore, technology implementation is 
rarely an instantaneous process resulting in 100% of uptake in the period after research results became 
available. A variety of NICE implementation uptake reports suggest that health technologies in the 
British National Health Service diffuse gradually over time (see for instance NICE (2010) or NICE 
(2009)). Adjusting the PEVI by uptake estimates of static or, ideally, dynamic nature would therefore 
result in more realistic estimates of the value of further research.  
Complexity is added through the potential inter-dependence between uptake and information. Uptake 
may be dependent on the level of information available to adopters and therefore be larger (or 
smaller) with perfect information than with less than perfect information. This has been discussed 
previously by Hoomans, Fenwick et al. (2009). In such a setting, two uptake estimates or curves 
would be needed for current and perfect information. 
With this background, the objective of this research was to investigate how population estimates for 
EVI analyses were obtained and whether uptake estimates or dynamics were used and what methods 
of obtaining them were employed. We therefore conducted a review of PEVI analyses with the 
following research questions in mind: how was the population estimate obtained? Was the population 
estimate adjusted by uptake? How was the estimate of uptake obtained? Was the issue of uncertainty 
associated with the population estimate discussed?  
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Methods 
The search was conducted using the NHS Economic Evaluation Database (EED). Search terms were: 
((Value of Information) OR EVI OR VOI). Titles and abstracts were screened and publications 
excluded when they did not report PEVI analyses or in the event of duplicates. Full texts of the 
included publications were then reviewed according to the research questions. Additional PEVI 
analyses that were known to us but did not come up through this small-scale search were also 
included. 
 
Results 
The NHS CRD search resulted in 43 hits. The titles and abstracts of all results were screened and 10 
publications were excluded as no EVI analysis had been performed and another 4 were excluded as no 
population EVI had been reported. Another publication was excluded because it resulted from an 
analysis already described in another included publication. One publication stated that EVI analysis 
had been conducted but did not detail methods or results and instead referenced another publication. 
Hence, the former was excluded and the latter included. For 2 other publications, full texts could not 
be obtained and they were therefore excluded. Three additional publications with EVI analyses that 
had not come up through this search but were known to us from elsewhere were included.  
We therefore included a total of 29 publications and examined them with regards to the research 
questions. Results are shown in detail in Table 1 in the appendix and are described below.  
In 27 out of the included 29 publications, the population size was not adjusted by uptake of the 
intervention. In those analyses, the population estimate was mainly obtained through the incidence 
and prevalence of the condition or the number of annual procedures. An uptake level of 100% was 
implicitly assumed in those cases.  
Only 2 studies had adjusted the population estimate by uptake. One of these, on thrombo-prophylaxis 
in post-hip replacement patients, acknowledged the dependence of uptake on information and reported 
2 different estimates of uptake: one conditional on perfect information and one for current information 
(McCullagh, Walsh et al. 2012). The uptake estimate for perfect information was obtained from a trial 
that had reported the proportion of patients receiving American College of Chest Physicians 
recommended prophylaxis and, for the current information scenario, an assumption was made.  
The second study used an uptake estimate which was obtained from a trial that had reported the use of 
trastuzumab adjuvant to chemotherapy in early stage breast cancer (Hall, Hulme et al. 2011). Neither 
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of the two studies had used a dynamic estimate of uptake or accounted for uncertainty associated with 
it. 
Five studies mentioned the issue of uncertainty associated with the population estimates in their PEVI 
analysis; four in their discussion and one implicitly by reporting different PEVI results with varying 
population estimates. In 1 of the 5 studies, it was stated that implementation of research results may 
not automatically happen after they became available and further exploration of this topic was 
recommended. None of the 5 studies, however, fully accounted for uncertainty by modelling the 
population estimate probabilistically. 
 
Discussion 
Our review has shown that the majority of EVI analyses do not consider uptake adjustments in their 
population estimates. The implication is that most reported values for the PEVI are likely to be an 
over-estimate of the actual value of further research as low uptake causes the population benefitting 
from further research to be smaller than the potentially eligible population.  
As the PEVI is viewed as an upper ceiling to the value of further research, assuming an uptake level 
of 100% is not wrong per se. It could simply be argued that this reflects the value of further research 
in a best-case and full uptake scenario. It should, however, be highlighted that this value might never 
be reached due to barriers to implementation. In cases where an uptake level of 100% is unachievable, 
potentially due to strong competition or other barriers, ignoring uptake from the PEVI estimate would 
result in a drastic over-statement of the value of further research and therefore have the potential to 
mislead decision-makers. 
With this study, we would like to spark a discussion on the need for adjusting population estimates by 
uptake. In the case that research is technology-specific and the level of uptake of that technology is 
foreseen to be below 100%, we think it essential to acknowledge this in the development of PEVI 
estimates. We also think that further research is needed on how uptake estimates can be obtained to 
inform such analyses. 
Limitations of this study include the small scope of the search. It is improbable that all PEVI analyses 
in health technologies have been captured with the adopted search strategy and there may be further 
examples out there that incorporated uptake estimates in their analysis. We do think, however, that 
with 27 out of 29 analyses estimating the population without an uptake adjustment and none including 
uptake dynamics, our findings are fairly representative of common practice and can be used as the 
basis for this discussion. 
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Further research could include, firstly, a broadening of the review and secondly, exploring and 
developing methods to include uptake estimates in PEVI analysis. The former could be achieved by 
broadening the search to other databases which would likely lead to inclusion of more EVI analyses. 
The inclusion of related methodology papers could also be considered. We do not, however, anticipate 
a significant change in results. 
As for exploring how to include uptake estimates in PEVI studies, we see two main areas of research. 
One is to address the question of how uptake estimates of both, static and dynamic nature, can be 
obtained. The two studies in this review that had used uptake estimates had obtained them from 
available trials and assumed that this level of uptake would hold throughout the time horizon adopted. 
Other ways of obtaining uptake estimates may include modelling future uptake probabilistically, with 
probability distributions obtained from using elicitation of expert opinions. As technology 
implementation is regarded as a dynamic process, there is further research potential on the way a 
dynamic uptake model could be estimated. 
More scope for further research is seen in the modelling implications of incorporating uptake into 
PEVI analysis. As was highlighted above, uptake levels may depend on information and, for instance, 
differ from current to perfect information. It is not unthinkable that, conversely, information may be 
dependent on uptake in that further research would only be conducted if patients are using an 
intervention. Exploring the modelling of such inter-dependencies between uptake and information 
provides potential direction for further research.  
In conclusion, we think that based on the result that very few PEVI studies had adjusted their 
population estimate by uptake and taking into account the large downward effect that uptake 
adjustments could have on the value of PEVI estimates, there is a need for discussion and further 
research around uptake adjustments in PEVI analyses. 
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Appendix 
Table 1. Review of PEVI analyses and the role of uptake in population estimates 
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1 McCulla
gh, 
Walsh et 
al. 
(2012) 
Prophylaxis of 
venous 
thromboembol
ysm after hip 
replacement 
Rivaroxaban, 
dagibatran 
etexilate, 
enoxaparin 
sodium 
THR 
procedures in 
acute public 
hospitals in 
Ireland and 
uptake 
Yes a) 64% for 
perfect 
information, 
b) 50% for 
current 
information 
a) Trial that 
reported 
proportion of 
patients 
receiving 
American 
College of 
Chest 
Physicians 
recommended 
prophylaxis, 
b) assumption 
It was 
acknowledged 
that population 
estimates for 
PEVI were 
themselves 
subject to 
uncertainty, 
however this was 
not explored. 
2 Welton, 
Ades et 
al. 
(2008) 
Low uptake of 
breast cancer 
screening 
Do nothing, 
send letter, flag 
in patient 
record, letter 
and flag 
Women 
eligible for 
screening  
No 100% 
(implicitly) 
- - 
3 Fleurenc
e (2007) 
Two case 
studies: 1. risk 
of fracture in 
osteoporosis 
patients and 2. 
pressure 
ulcers 
1. Hormone 
replacement 
therapy, 
bisphosphonates
, vitamin D with 
or without 
calcium, hip 
protectors, 2. 
High-spec foam 
mattress, 
alternating 
pressure 
mattresses and 
overlays  
Number of 
patients 
entering the 
decision in 
each year 
No 100% 
(implicitly) 
- The 
implementation of 
research results 
will not 
automatically 
follow the logical 
implications of 
the cost-
effectiveness 
evidence and 
should therefore 
be explored 
further in EVI 
analysis. 
4 Pandor, 
Eastham 
et al. 
(2004) 
Neonatal 
screening for 
inborn errors 
of metabolism 
Neonatal 
tandem mass 
spectrometry, 
no treatment 
Number of 
neonates per 
annum  
No 100% 
(implicitly) 
- - 
5 Soares, 
Welton 
et al. 
(2012) 
Severe sepsis 
and septic 
shock 
Adjuvant 
intravenous 
immunoglobulin
, current care 
Incidence No 100% 
(implicitly) 
- - 
6 Hall, 
McCabe 
et al. 
(2012) 
Early stage 
lymph node 
positive breast 
cancer 
Oncotype DX 
21-gene assay 
directed 
chemotherapy, 
chemotherapy 
for all 
Incidence No 100% 
(implicitly) 
- - 
7 Gurusa
my, 
Wilson 
et al. 
(2012) 
Gallbladder 
and common 
bile duct 
stones (CBD) 
Intra-operative 
versus pre-
operative 
endoscopic 
sphincterotomy 
(ES) 
Number of 
patients with 
laparoscopic 
cholecystecto
my with CBD 
stones and the 
number of ES 
performed 
each year 
No 100% 
(implicitly) 
- - 
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8 Pham, 
Teague 
et al. 
(2011) 
Pressure 
ulcers in 
elderly 
patients 
admitted 
through 
emergency 
departments 
Pressure re-
distributing 
foam 
mattresses, 
standard 
hospital 
mattresses 
Elderly 
admitted 
emergency 
department 
patients in 
Ontario 
No 100% 
(implicitly) 
- - 
9 Purmon
en, 
Pankalai
nen et 
al. 
(2011) 
Human 
epidermal 
growth factor 
Receptor 2 
(HER2)-
positive early 
breast cancer 
Adjuvant 
trastuzumab, 
conventional 
treatment after 
chemotherapy 
Number of 
HER2-
positive breast 
cancer 
patients 
No 100% 
(implicitly) 
- - 
10 Nosyk, 
Sharif et 
al. 
(2011) 
Influenza in 
patients with 
human 
immunodefici
ency virus 
Three influenza 
vaccine dosing 
strategies, 
previous dosing 
strategy 
Prevalence of 
HIV positive 
individuals in 
Canada 
No 100% 
(implicitly) 
- - 
11 Hall, 
Hulme 
et al. 
(2011) 
Human 
epidermal 
growth factor 
Receptor 2 
(HER2)-
positive early 
breast cancer 
Adjuvant 
trastuzumab, 
conventional 
treatment after 
chemotherapy 
Annual 
incidence of 
breast cancer 
and rate of 
over-
expression of 
HER2 and 
uptake 
Yes 67% Estimates of 
use of 
chemotherapy 
with adjuvant 
trastuzumab 
from a study 
- 
12 Petrou, 
Dakin et 
al. 
(2010) 
Otitis media 
with effusion 
Topical 
intranasal 
steroids, no 
treatment 
Number of 
children 
potentially 
eligible based 
on a trial 
No 100% 
(implicitly) 
- - 
13 Wilson, 
Gurusa
my et al. 
(2010) 
Acute 
cholecystitis 
Early versus 
delayed 
laparoscopic 
cholecystectom
y 
Number of 
laparoscopic 
cholecystecto
my per annum 
No 100% 
(implicitly) 
- - 
14 Eddama, 
Petrou 
et al. 
(2010) 
Pre-term birth 
in twins 
Progesterone 
gel, no 
treatment 
Estimated 
number of 
twin 
pregnancies 
per annum 
No 100% 
(implicitly) 
- - 
15 Stevens
on, 
Scope et 
al. 
(2010) 
Post-natal 
depression 
(PND) 
Group 
Cognitive 
Behavioural 
Therapy, routine 
care 
Annual 
incidence of 
PND 
No 100% 
(implicitly) 
- - 
16 Genders
, 
Meijboo
m et al. 
(2009) 
Suspected 
coronary 
artery disease 
Computer-
tomographic 
coronary 
angiography 
prior to 
conventional 
angiography, 
conventional 
coronary 
angiography 
Incidence No 100% 
(implicitly) 
- - 
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17 Bansbac
k, Ara et 
al. 
(2009) 
Rheumatoid 
arthritis (RA) 
Statin therapy in 
addition to 
conventional 
treatment, 
conventional 
treatment 
Number of 
RA patients 
No 100% 
(implicitly) 
- - 
18 Ramsey, 
Blough 
et al. 
(2008) 
Emphysema Lung-volume 
reduction 
surgery, medical 
treatment 
Number of 
procedures 
per annum 
No 100% 
(implicitly) 
- Acknowledged 
that there was 
uncertainty 
associated with 
the number of 
procedures but did 
not address this in 
the model. 
19 
 
Wailoo, 
Sutton 
et al. 
(2008) 
Influenza Amantadine, 
zanamivir, 
oseltamivir 
Influenza 
attack rate in 
healthy 
population 
and rate of 
influenza like 
illness 
No 100% 
(implicitly) 
- Acknowledged 
uncertainty 
associated with 
the population 
estimate but did 
not address this in 
the model. 
20 Singh, 
Nosyk 
et al. 
(2008) 
Patients with 
chest 
discomfort 
presenting to 
emergency 
department 
Early 
Disposition 
Prediction Rule, 
standard care 
Number of 
individuals 
presenting to 
emergency 
departments 
with chest 
discomfort 
each year 
No 100% 
(implicitly) 
- EVPI was 
reported with 
different levels of 
incidence; 
implementation 
was not discussed. 
21 Griebsc
h, 
Knowle
s et al. 
(2007) 
Newborn 
screening for 
congenital 
heart defects 
Clinical 
examination, 
pulse oximetry, 
echocardiograph
y 
Number of 
newborns 
No 100% 
(implicitly) 
- - 
22 Girling, 
Freeman 
et al. 
(2007) 
End-stage 
heart failure 
Left-ventricular 
assist device 
implantation vs. 
optimal medical 
management 
Cases of 
ESHF per 
annum 
No 100% 
(implicitly) 
- - 
23 Colbour
n, 
Assebur
g et al. 
(2007) 
Prevention of 
group B 
streptococcal 
and other 
bacterial 
infections in 
early infancy 
Prenatal 
screening and 
treatment 
strategies 
UK 
population 
No 100% 
(implicitly) 
- - 
24 Wight, 
Chilcott 
et al. 
(2003) 
Preserving 
kidneys prior 
to 
transplantatio
n 
Pulsatile 
machine 
perfusion, cold 
storage 
Transplant 
population 
No 100% 
(implicitly) 
- - 
25 Mahesw
aran and 
Barton 
(2012) 
Tuberculosis 
in HIV 
infected 
individuals  
9 different 
screening 
strategies in 
combination 
with Isoniazid 
Preventative 
Therapy 
Annual HIV 
incidence 
No 100% 
(implicitly) 
- - 
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26 McKenn
a, 
Walker 
et al. 
(2012) 
Post-
myocardial 
infarction 
(MI) heart 
failure 
Eplerenone, 
spironolactone 
Prevalence 
and incidence 
of post-MI 
heart failure 
No 100% 
(implicitly) 
- - 
27 Mohseni
nejad, 
van Baal 
et al. 
(2013) 
Prevention of 
depression 
Opportunistic 
screening and 
contact 
psychotherapy, 
no screening 
Prevalence of 
subthreshold 
depression 
No 100% 
(implicitly) 
- - 
28 Dallat, 
Hunter 
et al. 
(2013) 
Quality of life 
and 
absenteeism 
from work 
Monitoring 
physical activity 
at work, not 
monitoring 
All current 
Northern 
Ireland 
employees 
No 100% 
(implicitly) 
- - 
29 Murphy, 
Fenwick 
et al. 
(2013) 
Severe aortic 
stenosis 
Transcatheter 
aortic valve 
implantation, 
medical 
management 
Annual 
number of 
patients 
ineligible for 
surgery 
No 100% 
(implicitly) 
- - 
 
  
10 
 
References 
 
Bansback, N., R. Ara, et al. (2009). "Statin Therapy in Rheumatoid Arthritis: A Cost-Effectiveness 
and Value-of-Information Analysis." Pharmacoeconomics 27(1): 25-37. 
Colbourn, T., C. Asseburg, et al. (2007). "Prenatal screening and treatment strategies to prevent group 
B streptococcal and other bacterial infections in early infancy: cost-effectiveness and 
expected value of information  analyses." Health Technology Assessment 11(29). 
Dallat, M., R. Hunter, et al. (2013). "A lesson in business: cost-effectiveness analysis of a novel 
financial incentive intervention for increasing physical activity in the workplace." BMC 
Public Health 13: 953. 
Eddama, O., S. Petrou, et al. (2010). "Study of progesterone for the prevention of preterm birth in 
twins (STOPPIT): Findings from a trial-based cost-effectiveness analysis." International 
Journal of Technology Assessment in Health Care 26(2): 141-148. 
Fenwick, E., K. Claxton, et al. (2008). "The value of implementation and the value of information: 
combined and uneven development." Med Decision Making 28(1): 21-32. 
Fleurence, R. (2007). "Setting priorities for research: a practical application of 'payback' and expected 
value of information." HEALTH ECONOMICS 16(12): 1345-1357. 
Genders, T., W. Meijboom, et al. (2009). "CT Coronary Angiography in Patients Suspected of Having 
Coronary Artery Disease: Decision Making from Various Perspectives in the Face of 
Uncertainty." Radiology 253(3): 734-744. 
Girling, A., G. Freeman, et al. (2007). "Modeling payback from research into the efficacy of left-
ventricular assist devices as destination therapy." International Journal of Technology 
Assessment in Health Care 23(2): 269-277. 
Griebsch, I., R. Knowles, et al. (2007). "Comparing the clinical and economic effects of clinical 
examination, pulse oximetry, and echocardiography in newborn screening for congenital heart 
defects: A probabilistic cost-effectiveness model and value of information analysis." 
International Journal of Technology Assessment in Health Care 23(2): 192-204. 
Gurusamy, K., E. Wilson, et al. (2012). "Intra-Operative vs Pre-Operative Endoscopic 
Sphincterotomy in Patients with Gallbladder and Common Bile Duct Stones - Cost-Utility 
and Value-of-Information Analysis." Applied Health Economics & Health Policy 10(1): 15-
29. 
Hall, P., C. Hulme, et al. (2011). "Updated Cost-Effectiveness Analysis of Trastuzumab for Early 
Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and 
Pattern of Recurrence." Pharmacoeconomics 29(5): 415-432. 
Hall, P., C. McCabe, et al. (2012). "Economic evaluation of genomic test-directed chemotherapy for 
early stage lymph-node positive breast cancer." Journal of the National Cancer Institute 
104(1). 
11 
 
Hoomans, T., E. Fenwick, et al. (2009). "Value of Information and Value of Implementation: 
Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic 
Hormone-Refractory Prostate Cancer." Value in Health 12(2): 315-324. 
Maheswaran, H. and P. Barton (2012) "Intensive case finding and isoniazid preventative therapy in 
HIV infected individuals in Africa: economic model and value of information analysis." 
PLOS ONE 7. 
McCullagh, L., C. Walsh, et al. (2012). "Value-of-information analysis to reduce decision uncertainty 
associated with the choice of thromboprophylaxis after total hip replacement in the Irish 
health care setting." Pharmacoeconomics 30(10): 941-959. 
McKenna, C., S. Walker, et al. (2012). "Cost-effectiveness of aldosterone antagonists for the 
treatment of post-myocardial infarction heart failure." Value in Health 15(3): 420-428. 
Mohseninejad, L., P. van Baal, et al. (2013). "Value of information analysis from a societal 
perspective: a case study in prevention of major depression." Value in Health 16(4): 490-497. 
Murphy, A., E. Fenwick, et al. (2013). "Transcatheter aortic valve implantation for severe aortic 
stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom." 
International Journal of Technology Assessment in Health Care 29(1): 12-19. 
NICE (2009). NICE implementation uptake report: Capecitabine and oxaliplatin in the adjuvant 
treatment of stage III colon cancer, NICE. 
NICE (2010). NICE implementation uptake report: Laparoscopic surgery for inguinal hernia repair, 
NICE. 
Nosyk, B., B. Sharif, et al. (2011). "The Cost-Effectiveness and Value of Information of Three 
Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency 
Virus." PLoS ONE [Electronic Resource] 6(12). 
Pandor, A., J. Eastham, et al. (2004). "Clinical effectiveness and costeffectiveness of neonatal 
screening for inborn errors of metabolism using tandem mass spectrometry: a systematic 
review." Health Technology Assessment 8(12). 
Petrou, S., H. Dakin, et al. (2010). "Cost–Utility Analysis of Topical Intranasal Steroids for Otitis 
Media with Effusion Based on Evidence from the GNOMETrial." Value in Health 13(5): 543-
551. 
Pham, B., L. Teague, et al. (2011). "Early Prevention of Pressure Ulcers Among Elderly Patients 
Admitted Through Emergency Departments: A Cost-effectiveness Analysis." Annals of 
Emergency Medicine 58(5): 468-478. 
Philips, Z., K. Claxton, et al. (2008). "The half-life of truth: What are appropriate time horizons for 
research decisions?" Medical Decision Making 28: 287-299. 
Purmonen, T., E. Pankalainen, et al. (2011). "Short-course adjuvant trastuzumab therapy in early stage 
breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-
year follow-up results of the  inHer Trial." Acta Oncologica 50: 344-352. 
12 
 
Ramsey, S., D. Blough, et al. (2008). "A Forensic Evaluation of the National Emphysema Treatment 
Trial Using the Expected Value of Information Approach." Medical Care 46(5): 542-548. 
Singh, S., B. Nosyk, et al. (2008). "Value of information of a clinical prediction rule: informing the 
efficient use of healthcare and health research resources." International Journal of Technology 
Assessment in Health Care 24(1): 112-119. 
Soares, M., N. Welton, et al. (2012). An evaluation of the feasibility, cost and value of information of 
a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe 
sepsis and septic shock): incorporating a systematic review, meta-analysis and value of 
information analysis. Health Technology Assessment. N. HTA. 16. 
Stevenson, M., A. Scope, et al. (2010). "The Cost-Effectiveness of Group Cognitive Behavioral 
Therapy Compared with Routine Primary Care forWomen with Postnatal Depression in the 
UK." Value in Health 13(5): 580-584. 
Wailoo, A., A. Sutton, et al. (2008). "Cost-Effectiveness and Value of Information Analyses of 
Neuraminidase Inhibitors for the Treatment of Influenza." Value in Health 11(2): 160-171. 
Welton, N., A. E. Ades, et al. (2008). "Research prioritization based on expected value interventions 
to increase uptake of breast cancer screening." J R Statistical Society Series A 171(4): 1. 
Wight, J., J. Chilcott, et al. (2003). "The clinical and cost-effectiveness of pulsatile machine perfusion 
versus cold storage of kidneys for transplantation retrieved from heartbeating and non-heart-
beating donors." Health Technology Assessment 7(25). 
Wilson, E., K. Gurusamy, et al. (2010). "Cost–utility and value-of-information analysis of early 
versus delayed laparoscopic cholecystectomy for acute cholecystitis." British Journal of 
Surgery 97: 210-219. 
 
 
13 
 
